| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Annona atemoya Seed Extract - Atemoya Seed Extract Abbreviation: AAS, EEAA for ethanol extract Type: Botanical seed extract / acetogenin-rich plant product Source: Seeds of Annona atemoya. Active Constituents: Annona atemoya seeds contain annonaceous acetogenins including bullatacin and related cytotoxic acetogenins, together with other phytochemical constituents. Function: Annona atemoya seed extract exhibits anti-angiogenic and antiproliferative activity in experimental models. Its effects include inhibition of endothelial-cell proliferation, migration, and tube formation and suppression of hypoxia-responsive angiogenic signaling. Cancer: Preclinical studies show anti-angiogenic activity in vitro and in vivo. Ethanol extract of Annona atemoya seeds suppresses tumor-associated angiogenesis and reduces HIF-1α, HIF-2α, and VEGF expression under hypoxic conditions. Acetogenins such as bullatacin may also contribute direct cytotoxic and pro-apoptotic effects. Clinical anticancer efficacy has not been established. Annona atemoya Seed Extract — A botanical extract prepared from the seeds of Annona atemoya, a hybrid of Annona squamosa and Annona cherimola. It is an acetogenin-rich botanical product with experimental anti-angiogenic and cytotoxic activity. Standard abbreviations are AAS for Annona atemoya seed material and EEAA for ethanol extract of Annona atemoya seeds. The seeds contain particularly high concentrations and diversity of annonaceous acetogenins, including bullatacin, bullatanocin, squamocin derivatives, atemoyacins, annotemoyins and related compounds. Unlike the edible fruit pulp, the seeds should not be regarded as a conventional food ingredient because acetogenin-rich seed extracts have substantial experimental neurotoxicity. Primary mechanisms (ranked):
Bioavailability / PK relevance: Human pharmacokinetics, systemic bioavailability, therapeutic dosing and standardized extract composition have not been established. Acetogenins are lipophilic constituents, and extract composition varies substantially with solvent, cultivar and preparation. There is no validated human exposure range corresponding to the concentrations producing anticancer effects experimentally. In-vitro vs systemic exposure relevance: Most anticancer evidence derives from purified acetogenins, cultured cells, endothelial assays and animal angiogenesis or xenograft models. Whether active concentrations can be achieved safely in humans is unknown. This is particularly important because mitochondrial complex-I inhibition is not cancer-specific and acetogenin-rich Annona seed extracts demonstrate potent neuronal toxicity experimentally. Clinical evidence status: Preclinical only. Anti-angiogenic effects have been demonstrated in vitro and in animal models, and isolated seed acetogenins have shown strong cytotoxicity and some xenograft activity. No established human anticancer efficacy, validated clinical dosing regimen or approved therapeutic use was identified. Safety is a major translational limitation, particularly potential acetogenin-associated neurotoxicity. Mechanistic Effects of Annona atemoya Seed Extract
|
| Source: |
| Type: |
| custom |
| 7981- | AAS/EEAA, | Chemopreventive Potential of Oils Extracted from Seeds of Three Annona Species |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:469 Target#:767 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid